<p>藥明康德（NASDAQ:OTLK - 獲取免費報告）的股票目前被七家評級公司給予了 “買入” 的平均評級，Marketbeat.com 報道。七位分析師對該股票給予了買入評級。在過去一年中，覆蓋該股票的經紀人給出的平均十二個月目標價為 48.20 美元。</p>
<p>獲取 <strong>Outlook Therapeutics</strong> 的提醒：</p>
<ul>
<li>3 只被低估的製藥股，具備上漲催化劑</li>
</ul>
<p>幾位研究分析師最近對該公司進行了評論。Ascendiant Capital Markets 將藥明康德的目標價從 35.00 美元下調至 33.00 美元，並在 9 月 3 日的研究報告中給予該股票 “買入” 評級。HC Wainwright 在 8 月 15 日的研究報告中重申了 “買入” 評級，並對藥明康德的股票設定了 30.00 美元的目標價。Chardan Capital 在 8 月 16 日的研究報告中重新發布了 “買入” 評級，並將藥明康德的目標價設定為 53.00 美元。最後，BTIG Research 在 10 月 18 日的報告中重申了 “買入” 評級，並對藥明康德的股票設定了 50.00 美元的目標價。</p>
<p><strong>查看我們對藥明康德的最新股票分析</strong></p>
<h2>藥明康德的價格表現</h2>
<ul>
<li>MarketBeat 週報 – 6/17 - 6/21</li>
</ul>
<p>NASDAQ OTLK 的股票在週三以 5.74 美元開盤。該公司的市值為 1.3579 億美元，市盈率為-0.50，貝塔值為 0.62。藥明康德的 1 年最低價為 4.61 美元，1 年最高價為 13.32 美元。該公司的 50 日移動平均價為 6.16 美元，200 日移動平均價為 7.21 美元。</p>
<p>藥明康德（NASDAQ:OTLK - 獲取免費報告）最近在 8 月 14 日發佈了季度財報。該公司報告每股收益（EPS）為-0.83 美元，超出市場共識預期的-1.06 美元，超出幅度為 0.23 美元。研究分析師預計藥明康德在當前財年的每股收益將為-3.63 美元。</p>
<h2>藥明康德的內部買賣情況</h2>
<ul>
<li>藥明康德：分析師預測股票上漲超過 500%</li>
</ul>
<p>在其他藥明康德的新聞中，首席財務官 Lawrence A. Kenyon 在 9 月 26 日的交易中購買了 5,000 股該股票。該股票的平均購買價格為每股 5.69 美元，總價值為 28,450.00 美元。交易後，首席財務官現在直接持有該公司 5,946 股股票，價值約為 33,832.74 美元。這代表了他們持股比例的 500.00% 的增長。此次收購在向證券交易委員會的備案中披露，相關信息可通過此鏈接訪問。3.40% 的股票由內部人士持有。</p>
<h2>機構投資者對藥明康德的看法</h2>
<p>大型投資者最近增加或減少了對該股票的持股。Great Point Partners LLC 在第二季度將其在藥明康德的持股增加了 15.0%。Great Point Partners LLC 現在擁有 1,701,510 股該公司的股票，價值為 12,557,000 美元，此前在該期間內又收購了 221,510 股。Susquehanna Fundamental Investments LLC 在第二季度收購了藥明康德的新股份，價值約為 303,000 美元。Squarepoint Ops LLC 在第二季度購買了藥明康德的新股份，價值約為 232,000 美元。Christensen King &amp; Associates Investment Services Inc. 在第三季度收購了藥明康德的新職位，價值約為 55,000 美元。最後，AQR Capital Management LLC 在第二季度購買了藥明康德的新職位，價值約為 75,000 美元。11.20% 的股票由機構投資者和對沖基金持有。</p>
<h2>藥明康德公司簡介（獲取免費報告）</h2>
<p>藥明康德（Outlook Therapeutics, Inc.）是一家臨牀階段的生物製藥公司，專注於開發和商業化用於各種眼科適應症的單克隆抗體。其主要產品候選藥物是 ONS-5010，這是一種用於治療濕性年齡相關性黃斑變性和其他視網膜疾病的貝伐單抗眼科製劑，目前處於第三階段臨牀試驗中。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過藥明康德</li>
<li>什麼是分紅競爭者？投資分紅競爭者</li>
<li>麥當勞的股票在拋售和財報後是否值得購買？</li>
<li>為什麼除息日對投資者來説重要？</li>
<li>QuantumScape：固態電池即將商業化</li>
<li>投資者需要了解即將上市的 IPO</li>
<li>MicroStrategy：這隻比特幣驅動的股票是買入還是賭博？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1RMSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1RMSw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<p>→ 埃隆全力支持特朗普的真正原因（來自 Porter &amp; Company）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05OTYw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05OTYw"/></p>
<h2>你現在應該投資 1,000 美元在藥明康德嗎？</h2>
<p>在考慮藥明康德之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而藥明康德並不在名單上。</p>
<p>雖然藥明康德目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

OTLK

<p>Outlook Therapeutics, Inc.（納斯達克代碼：OTLK）獲得了七家券商的一致 “買入” 評級。分析師設定的平均十二個月目標價為 0.20 美元。最近的報告顯示，Ascendiant Capital Markets 將其目標價下調至 0.00 美元，但維持 “買入” 評級。該公司的市值為 7900 萬美元，報告每股收益為-0.83 美元，超出預期。首席財務官 Lawrence A. Kenyon 最近購買了 5000 股，顯著增加了他的持股比例。機構投資者持有該股票的 11.20%，多家公司的持股都有顯著增加</p>

<p>Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) have been given an average rating of &#34;Buy&#34; by the seven ratings firms that are presently covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have covered the stock in the last year is $48.20.</p>
<div class="lb-trans"><p>藥明康德（NASDAQ:OTLK - 獲取免費報告）的股票目前被七家評級公司給予了 “買入” 的平均評級，Marketbeat.com 報道。七位分析師對該股票給予了買入評級。在過去一年中，覆蓋該股票的經紀人給出的平均十二個月目標價為 48.20 美元。</p>
</div><p>Get <strong>Outlook Therapeutics</strong> alerts:</p>
<ul>
<li>3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices</li>
</ul>
<div class="lb-trans"><p>獲取 <strong>Outlook Therapeutics</strong> 的提醒：</p>
<ul>
<li>3 只被低估的製藥股，具備上漲催化劑</li>
</ul>
</div><p>Several research analysts recently commented on the company. Ascendiant Capital Markets cut their price target on Outlook Therapeutics from $35.00 to $33.00 and set a &#34;buy&#34; rating on the stock in a research note on Tuesday, September 3rd. HC Wainwright reaffirmed a &#34;buy&#34; rating and issued a $30.00 target price on shares of Outlook Therapeutics in a research report on Thursday, August 15th. Chardan Capital reissued a &#34;buy&#34; rating and set a $53.00 price target on shares of Outlook Therapeutics in a research report on Friday, August 16th. Finally, BTIG Research reaffirmed a &#34;buy&#34; rating and issued a $50.00 price target on shares of Outlook Therapeutics in a report on Friday, October 18th.</p>
<div class="lb-trans"><p>幾位研究分析師最近對該公司進行了評論。Ascendiant Capital Markets 將藥明康德的目標價從 35.00 美元下調至 33.00 美元，並在 9 月 3 日的研究報告中給予該股票 “買入” 評級。HC Wainwright 在 8 月 15 日的研究報告中重申了 “買入” 評級，並對藥明康德的股票設定了 30.00 美元的目標價。Chardan Capital 在 8 月 16 日的研究報告中重新發布了 “買入” 評級，並將藥明康德的目標價設定為 53.00 美元。最後，BTIG Research 在 10 月 18 日的報告中重申了 “買入” 評級，並對藥明康德的股票設定了 50.00 美元的目標價。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Outlook Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我們對藥明康德的最新股票分析</strong></p>
</div><h2>Outlook Therapeutics Price Performance</h2>
<ul>
<li>MarketBeat Week in Review – 6/17 - 6/21</li>
</ul>
<div class="lb-trans"><h2>藥明康德的價格表現</h2>
<ul>
<li>MarketBeat 週報 – 6/17 - 6/21</li>
</ul>
</div><p>Shares of NASDAQ OTLK opened at $5.74 on Wednesday. The company has a market capitalization of $135.79 million, a price-to-earnings ratio of -0.50 and a beta of 0.62. Outlook Therapeutics has a 1-year low of $4.61 and a 1-year high of $13.32. The business has a 50-day moving average of $6.16 and a 200-day moving average of $7.21.</p>
<div class="lb-trans"><p>NASDAQ OTLK 的股票在週三以 5.74 美元開盤。該公司的市值為 1.3579 億美元，市盈率為-0.50，貝塔值為 0.62。藥明康德的 1 年最低價為 4.61 美元，1 年最高價為 13.32 美元。該公司的 50 日移動平均價為 6.16 美元，200 日移動平均價為 7.21 美元。</p>
</div><p>Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.23. Research analysts expect that Outlook Therapeutics will post -3.63 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>藥明康德（NASDAQ:OTLK - 獲取免費報告）最近在 8 月 14 日發佈了季度財報。該公司報告每股收益（EPS）為-0.83 美元，超出市場共識預期的-1.06 美元，超出幅度為 0.23 美元。研究分析師預計藥明康德在當前財年的每股收益將為-3.63 美元。</p>
</div><h2>Insider Buying and Selling at Outlook Therapeutics</h2>
<ul>
<li>Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside</li>
</ul>
<div class="lb-trans"><h2>藥明康德的內部買賣情況</h2>
<ul>
<li>藥明康德：分析師預測股票上漲超過 500%</li>
</ul>
</div><p>In other Outlook Therapeutics news, CFO Lawrence A. Kenyon acquired 5,000 shares of the stock in a transaction that occurred on Thursday, September 26th. The stock was acquired at an average price of $5.69 per share, with a total value of $28,450.00. Following the transaction, the chief financial officer now directly owns 5,946 shares in the company, valued at approximately $33,832.74. This represents a 500.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this link. 3.40% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他藥明康德的新聞中，首席財務官 Lawrence A. Kenyon 在 9 月 26 日的交易中購買了 5,000 股該股票。該股票的平均購買價格為每股 5.69 美元，總價值為 28,450.00 美元。交易後，首席財務官現在直接持有該公司 5,946 股股票，價值約為 33,832.74 美元。這代表了他們持股比例的 500.00% 的增長。此次收購在向證券交易委員會的備案中披露，相關信息可通過此鏈接訪問。3.40% 的股票由內部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Outlook Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對藥明康德的看法</h2>
</div><p>Large investors have recently added to or reduced their stakes in the stock. Great Point Partners LLC increased its holdings in shares of Outlook Therapeutics by 15.0% in the 2nd quarter. Great Point Partners LLC now owns 1,701,510 shares of the company's stock worth $12,557,000 after acquiring an additional 221,510 shares during the period. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Outlook Therapeutics in the second quarter valued at approximately $303,000. Squarepoint Ops LLC bought a new stake in shares of Outlook Therapeutics during the second quarter valued at approximately $232,000. Christensen King &amp; Associates Investment Services Inc. acquired a new position in shares of Outlook Therapeutics during the third quarter worth approximately $55,000. Finally, AQR Capital Management LLC bought a new position in Outlook Therapeutics in the 2nd quarter worth approximately $75,000. 11.20% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>大型投資者最近增加或減少了對該股票的持股。Great Point Partners LLC 在第二季度將其在藥明康德的持股增加了 15.0%。Great Point Partners LLC 現在擁有 1,701,510 股該公司的股票，價值為 12,557,000 美元，此前在該期間內又收購了 221,510 股。Susquehanna Fundamental Investments LLC 在第二季度收購了藥明康德的新股份，價值約為 303,000 美元。Squarepoint Ops LLC 在第二季度購買了藥明康德的新股份，價值約為 232,000 美元。Christensen King &amp; Associates Investment Services Inc. 在第三季度收購了藥明康德的新職位，價值約為 55,000 美元。最後，AQR Capital Management LLC 在第二季度購買了藥明康德的新職位，價值約為 75,000 美元。11.20% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Outlook Therapeutics Company Profile (Get Free Report</h2>
<div class="lb-trans"><h2>藥明康德公司簡介（獲取免費報告）</h2>
</div><p>Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.</p>
<div class="lb-trans"><p>藥明康德（Outlook Therapeutics, Inc.）是一家臨牀階段的生物製藥公司，專注於開發和商業化用於各種眼科適應症的單克隆抗體。其主要產品候選藥物是 ONS-5010，這是一種用於治療濕性年齡相關性黃斑變性和其他視網膜疾病的貝伐單抗眼科製劑，目前處於第三階段臨牀試驗中。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Outlook Therapeutics</li>
<li>What Are Dividend Contenders? Investing in Dividend Contenders</li>
<li>Is McDonald's Stock a Smart Buy After Sell-Off and Earnings?</li>
<li>Why is the Ex-Dividend Date Significant to Investors?</li>
<li>QuantumScape: Solid State EV Batteries Nearing Commercialization</li>
<li>What Investors Need to Know About Upcoming IPOs</li>
<li>MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?</li>
</ul>
<div class="lb-trans"><h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過藥明康德</li>
<li>什麼是分紅競爭者？投資分紅競爭者</li>
<li>麥當勞的股票在拋售和財報後是否值得購買？</li>
<li>為什麼除息日對投資者來説重要？</li>
<li>QuantumScape：固態電池即將商業化</li>
<li>投資者需要了解即將上市的 IPO</li>
<li>MicroStrategy：這隻比特幣驅動的股票是買入還是賭博？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1RMSw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=OTLK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><p>→ The real reason Elon is fully endorsing Trump (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 埃隆全力支持特朗普的真正原因（來自 Porter &amp; Company）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05OTYw" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9960&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Outlook Therapeutics right now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在藥明康德嗎？</h2>
</div><p>Before you consider Outlook Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮藥明康德之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Outlook Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而藥明康德並不在名單上。</p>
</div><p>While Outlook Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然藥明康德目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Outlook Therapeutics, Inc.（納斯達克股票代碼：OTLK）獲得券商一致推薦的 “買入” 評級